Drug Profile
CVT 3501
Latest Information Update: 03 Feb 2003
Price :
$50
*
At a glance
- Originator CV Therapeutics
- Class Heart failure therapies; Ischaemic heart disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Angina pectoris; Heart failure
Most Recent Events
- 03 Feb 2003 No development reported - Preclinical for Angina pectoris in USA (unspecified route)
- 03 Feb 2003 No development reported - Preclinical for Congestive heart failure in USA (unspecified route)
- 13 Jul 2001 Preclinical development for Angina pectoris in USA (Unknown route)